Clinical trials: Zoledronic acid
Osteoporosis
Frequency of Zoledronic Acid to Prevent Further Bone Loss in Osteoporotic Patients Requiring Androgen Deprivation Therapy for Prostate Cancer
The aim of this study is to determine if 3 monthly infusions of zoledronic acid, given over one year, improves the bone mineral density in osteoporotic patients undergoing androgen deprivation therapy for prostate cancer
- Trial name
- NCT00520052
- Testing
- zoledronic acid
- Where
- United Kingdom
- Volunteers
- 58 people
- Sponsor
- Wirral University Teaching Hospital NHS Trust
Pre-integration Failure of Dental Implant
Initial Fixation of Bisphosphonate-coated Dental Implants
16 patients will be included. Each patient receives 2 dental implants. One of them is coated with a drug, zoledronate, to improve fixation.
- Trial name
- NCT02044978
- Testing
- Zoledronate-coated dental implant
- Where
- 2 sites in Sweden
- Volunteers
- 16 people
- Sponsor
- Per Aspenberg
Osteoporosis
Zometa Study in Pediatric Acute Lymphoblastic Leukemia
Acute Lymphoblastic Leukemia (ALL) is the most common malignancy in children. It accounts for one fourth of all childhood cancers \& 74 % of childhood leukemia.
- Trial name
- NCT01656512
- Testing
- zolendronic acid, calcium & vitamin D
- Where
- Egypt
- Volunteers
- 95 people
- Sponsor
- Children's Cancer Hospital Egypt 57357
Paget's Disease of the Bone
Re-treatment of Participants With Paget's Disease Using Zoledronic Acid
The purpose of this study was to demonstrate that participants with Paget's disease of the bone who had responded to zoledronic acid treatment as participants in the core registration studies CZOL446K2304 and CZOL446K2305 and…
- Trial name
- NCT00740129
- Testing
- Zoledronic Acid
- Where
- 11 sites in Belgium, Canada and 4 more
- Volunteers
- 6 people
- Sponsor
- Novartis Pharmaceuticals
Osteogenesis Imperfecta
Zoledronic Acid in Children (1 -17 Years) With Severe Osteogenesis Imperfecta
This is an extension study to examine the long-term safety and efficacy of zoledronic acid in patients who have completed the core CZOL446H2202 study.
- Trial name
- NCT00131118
- Testing
- Zoledronic Acid
- Where
- 10 sites in United States
- Volunteers
- 127 people
- Sponsor
- Novartis Pharmaceuticals
Lung Metastases, Tumor Necrosis
Zoledronic Acid in Decrease the Lung Metastatic Rate of Osteosarcoma
Zoledronic acid is an adjuvant treatment for primary osteosarcoma. Zoledronic acid has been widely used in the treatment of metastatic bone tumors.
- Trial name
- NCT03932071
- Testing
- Zoledronic Acid
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Atypical Femoral Fractures, Osteoporosis
Exome Sequencing for Atypical Femoral Fractures
The purpose of this study is to determine whether women who have atypical subtrochanteric and diaphyseal femoral fractures after treatment with bisphosphonates for osteoporosis, have a genetic predisposition to these unusual…
- Conditions
- Atypical Femoral Fractures, Osteoporosis, Bisphosphonate Therapy
- Trial name
- NCT02731040
- Testing
- Bisphosphonate
- Volunteers
- 38 people
- Sponsor
- Washington University School of Medicine
Prostate Cancer
Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy
The overall aim of this trial, which is called STAMPEDE, is to assess novel approaches for the treatment of men with prostate cancer who are starting long-term ADT for the first time, termed hormone-naïve prostate cancer.
- Trial name
- STAMPEDE (NCT00268476)
- Testing
- Celecoxib, Docetaxel, Prednisolone
- Where
- 120 sites in Switzerland, United Kingdom
- Volunteers
- 11,992 people
- Sponsor
- Medical Research Council
Solid Tumor, Osteosarcoma
Metronomic Chemotherapy in Patients With Advanced Solid Tumor With Bone Metastasis and Advanced Pretreated Osteosarcoma
This is a prospective open-labeled phase I trial based on a dose escalating study design assessing two dose levels of sirolimus when prescribed in combination with metronomic cyclophosphamide (CP), methotrexate (MT) and…
- Trial name
- METZOLIMOS (NCT02517918)
- Testing
- Sirolimus combined with CP, MT and ZA
- Where
- 3 sites in France
- Volunteers
- 23 people
- Sponsor
- Institut Bergonié
Orthodontic Appliance Complication
Effect of Local Subperiosteal Zoledronic Acid Injection on the Survival of Orthodontic Miniscrews
Background: Orthodontic miniscrews are widely used as temporary anchorage devices; however, failure remains a clinical concern. Bisphosphonates may enhance bone stability, but evidence on their local application is limited.
- Trial name
- NCT07546058
- Testing
- Zoledronic Acid, Normal saline (0.9% sodium chloride)
- Where
- Syria
- Volunteers
- 68 people
- Sponsor
- Latakia University
Malignant Neoplasm, Musculoskeletal Complications
Genetics in Predicting Risk of Bisphosphonate-Related Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid
This randomized clinical trial studies genetics in predicting risk of bisphosphonate-related osteonecrosis of the jaw in patients with cancer receiving zoledronic acid.
- Trial name
- NCT02069340
- Testing
- zoledronic acid, pharmacological study
- Where
- 2 sites in United States
- Sponsor
- University of Southern California
Neuroblastoma, Refractory Neuroblastoma
Allogeneic Expanded Gamma Delta T Cells With GD2 Chemoimmunotherapy in Relapsed /Refractory Neuroblastoma or Refractory/ Relapsed Osteosarcoma
The goal of this clinical trial is to determine the maximum tolerated dose (MTD) and recommended Phase II dose (RP2D) of allogeneic expanded γδ T cells when delivered with Dinutuximab, temozolomide, irinotecan, and zoledronate in…
- Conditions
- Neuroblastoma, Refractory Neuroblastoma, Relapsed Neuroblastoma, Relapsed Osteosarcoma
- Trial name
- Aflac-NBL-2002 (NCT05400603)
- Testing
- Ex Vivo Expanded Allogeneic γδ T Cells in Combination with Dinutuximab, Temozolomide, Irinotecan and Zoledronate
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Emory University
Bone Loss, Breast Cancer
Zoledronic Acid in the Prevention of Cancer Treatment Related Bone Loss in Postmenopausal Women Receiving Letrozole for Breast Cancer.
Post-menopausal breast cancer patients will receive letrozole 2.5 mg daily for the treatment of breast cancer and will be randomized to a treatment group to receive either upfront zoledronic acid 4 mg IV 15-minute infusion every…
- Trial name
- NCT00171340
- Testing
- Zoledronic acid, Letrozole
- Where
- 106 sites in Argentina, Australia and 26 more
- Volunteers
- 1,065 people
- Sponsor
- Novartis Pharmaceuticals
Sarcoma
Combined Chemotherapy With or Without Zoledronic Acid for Patients With Osteosarcoma
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- OS2006 (NCT00470223)
- Testing
- cisplatin, doxorubicin hydrochloride, etoposide
- Where
- 37 sites in France
- Volunteers
- 318 people
- Sponsor
- UNICANCER
Osteoporosis, Osteonecrosis
Intravenous Zoledronic Acid for the Treatment of Osteoporosis and Osteonecrosis in Children With Leukemia: A Pilot Study
This study explores the effect of zoledronic acid on incident vertebral fractures and osteonecrotic lesions in children recently diagnosed with acute lymphoblastic leukemia.
- Conditions
- Osteoporosis, Osteonecrosis, Acute Lymphoblastic Leukemia
- Trial name
- NCT02632903
- Testing
- Zoledronic acid
- Where
- Canada
- Sponsor
- Children's Hospital of Eastern Ontario
Osteoporosis
Effect of Zoledronic Acid on Femoral Bone Loss Following Total Hip Arthroplasty
In a randomized, double-blind trial, BMD of the operated proximal femur after total hip replacement measured by dual-energy x-ray absorptiometry (DXA) were compared for up to two years in patients receiving IV ZOL 5 mg infusion…
- Trial name
- NCT01267279
- Testing
- Zoledronic acid
- Volunteers
- 51 people, healthy volunteers welcome
- Sponsor
- Spokane Joint Replacement Center
NEUROBLASTOMA
Zoledronic Acid (ZOMETA) With Cyclophosphamide With Neuroblastoma and Cortical Bone Involvement
The purposes of this study are: 1. To find the highest dose of monthly intravenous Zometa that can be given with daily low doses of cyclophosphamide by mouth to children with recurrent or refractory neuroblastoma without causing…
- Trial name
- NCT00206388
- Testing
- Zolendric acid, Cyclophosphamide
- Where
- 8 sites in United States
- Volunteers
- 21 people
- Sponsor
- Baylor College of Medicine
Osteoporosis
Atorvastatin (Lipitor) to Prevent Bone Pain
In the proposed randomized double blind cross-over placebo controlled study, the researchers intend to investigate if Atorvastatin (FDA approved statin for children) can be used to alleviate the symptom of bone pain (acute phase…
- Trial name
- NCT00120133
- Testing
- Atorvastatin
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Children's Mercy Hospital Kansas City
Osteogenesis Imperfecta
Bisphosphonate Treatment of Osteogenesis Imperfecta
The primary purpose of this trial is to evaluate whether the investigational medication is safe, effective and has the ability to increase spine bone density in osteogenesis imperfecta (OI) patients.
- Trial name
- NCT00063479
- Testing
- Zoledronic Acid
- Where
- 10 sites in United States
- Volunteers
- 158 people
- Sponsor
- Novartis Pharmaceuticals
FHA (Functional Hypothalamic Amenorrhea)
Romosozumab as an Adjunct to Physiologic Estrogen Replacement in Functional Hypothalamic Amenorrhea
The goal of this study is to determine whether romosozumab will improve bone density in girls and women with functional hypothalamic amenorrhea (cessation of the menstrual period due to intense exercise, stress, or an eating…
- Trial name
- NCT06533865
- Testing
- Romosozumab, Zoledronic acid
- Where
- 2 sites in United States
- Volunteers
- 114 people
- Sponsor
- Massachusetts General Hospital